A new study suggests that adding a second drug to standard therapies for acute lymphocytic leukemia (ALL) may reduce or avoid heart damage, a frequent and serious side effect among children treated for this cancer.
A new study suggests that adding a second drug to standard therapies for acute lymphocytic leukemia (ALL) may reduce or avoid heart damage, a frequent and serious side effect among children treated for this cancer.
